Medigene AG (Medigene, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies ...
A five-year study has found that adding daratumumab (D) to the current standard-of-care triplet therapy bortezomib, lenalidomide, and dexamethasone (VRd) produced deeper and more durable minimal ...
American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA between February 13 th and 15 th 2025, was host to the Panning for Gold: The Role of ctDNA as ...
Guardant Health is overcoming skepticism with new cancer tests. Learn why GH stock is a buy, with strong growth and a shift ...
In 2024, Myriad Genetics was awarded three patents related to foundational platform MRD technology and cell-free DNA preparation methods that each enable highly sensitive and specific tumor-informed, ...
Despite research showing the benefits of circulating tumor DNA as an indicator of disease remission in B-cell lymphoma, ...
Barrier methods of birth control physically block sperm from reaching the uterus during sexual activity. There are many types to choose from. Weigh up the pros and cons of each before deciding ...
In 2024, Myriad Genetics was awarded three patents related to foundational platform MRD technology and cell-free DNA preparation methods that each enable highly sensitive and specific tumor ...
These patents build on three foundational MRD technology patents awarded to Myriad Genetics in 2024, which relate to cell-free DNA preparation methods and enable highly sensitive tumor-informed ...
In 2024, Myriad Genetics was awarded three patents related to foundational platform MRD technology and cell-free DNA preparation methods that each enable highly sensitive and specific tumor-informed, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback